OpenResearchAlpha

Journal of Physiology and Biochemistry · 12 Nov 2026

A pilot study on the impact of Hydroxiram D supplementation on nutritional status and sarcopenia-related parameters

Paolo Gallo, Valentina Flagiello, Simone Di Cola, Lucrezia Santoro, Dafne Marcelli, Giorgio Reggiardo, Francesca Terracciani, Andrea Falcomatà, Antonio De Vincentis, Antonio Picardi, Raffaele Antonelli-Incalzi, Umberto Vespasiani-Gentiluccih-index 24

0
Citations
no database records one yet
0
Citations in 2026
so far
24
Leading author's h-index
Umberto Vespasiani-Gentilucci, in QAI's scholar index
29
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Sarcopenia is a frequent and prognostically relevant complication of chronic liver disease. The SARCIRAM pilot trial investigated the effect of Hydroxiram D, a formulation of branched-chain amino acids (BCAAs), β-hydroxy-β-methylbutyrate (HMB), and vitamin D, on nutritional status and sarcopenia-related parameters in patients with compensated cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD). In this single-center, randomized pilot study, adults with compensated MASLD-related cirrhosis (Child-Pugh A) received Hydroxiram D plus standard care or standard care alone for 6 months. The primary outcome was phase angle (PA), while secondary outcomes were appendicular skeletal muscle mass (ASMM)/height², handgrip strength (HGS), and 4-meter walk test (4-mWT). Between-group comparisons used baseline-adjusted models. Post-hoc simulation analyses were used exploratorily to inform the design of future studies. Thirty-two patients were analyzed. After 6 months, the adjusted change in PA was significantly more favorable in the treated group versus controls (+ 0.36° vs. − 0.45°, p = 0.046). Between-group differences in muscle mass, HGS, and gait speed were not statistically significant, although effect estimates directionally favoured the intervention. No treatment-related adverse events were observed. Six months of Hydroxiram D was associated with a more favorable change in PA in patients with compensated MASLD-related cirrhosis, with favorable trends in muscle parameters. These hypothesis-generating findings warrant confirmation in larger, prospectively registered, double-blind trials to confirm efficacy and long-term outcomes.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Umberto Vespasiani-Gentilucci has the highest h-index among the authors (24).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (12)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (29)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 9 more references

A free account opens the rest of the citing papers and references on every paper’s page.